Fractional CO2 laser, platelet rich plasma and narrow band ultraviolet B in the treatment of Vitiligo (A randomized clinical trial)

Afify, A. A.; Zuel-Fakkar, Nehal Mohamed; Eshafi, Mohamed Abdullah

doi:10.1007/s10103-020-03195-9

Cited by 19 publications

(33 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, combination therapy group demonstrated higher percentages of excellent response rate in leg and forearm areas (75% and 50%, respectively) compared to other body sites (42.8%, 25%, and 14.2% in knee, feet and elbow areas, respectively), but the results were not significant. In the current study, type of repigmentation in most of the cases in both treatment groups was both follicular and diffuse types that were similar to the ones by treatment modalities including immunomodulators and phothotherapy 13,14 . Most of the treatment modalities for vitiligo have poor efficacy on acral areas and lesions on bony prominence due to absence or low numbers of hair follicles 17,18 .…”

Section: Discussionsupporting

confidence: 58%

“…3,4 There are several studies that evaluates efficacy of combination of NB-UVB with different treatment modalities. [13][14][15][16][17][18][19][20] In one prospective right/left comparison study, Goktas et al evaluated efficacy of combined NB-UVB and calcipotriol compared to NB-UVB alone during 6 months. Excellent response rates for extremity lesions in combination and monotherapy groups were 25% and 10.7%, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…In the current study, type of repigmentation in most of the cases in both treatment groups was both follicular and diffuse types that were similar to the ones by treatment modalities including immunomodulators and phothotherapy. 13,14 Most of the treatment modalities for vitiligo have poor efficacy on acral areas and lesions on bony prominence due to absence or low numbers of hair follicles. 17,18 However, in this study adding carboxytherapy to NB-UVB leads to higher response rate in acral areas compared to previous studies.…”

Section: Resultsmentioning

confidence: 99%

“…NB‐UVB induces immunomodulation, stimulates proliferation and migration of melanocytes from perilesional skin and hair follicles by inhibition of cytotoxic T cells, releasing anti‐inflammatory cytokines (such as IL‐4 and IL‐10) and melanogenic factors (endotheline‐1, melanocyte stimulating hormone [MSH] and stem cell factor [SCF]) 3,4 . There are several studies that evaluates efficacy of combination of NB‐UVB with different treatment modalities 13–20 …”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Combination of carboxytherapy with narrowband‐ultraviolet B in the treatment of recalcitrant areas of vitiligo: A randomized clinical trial

Farajzadeh

Yazdanpanah

Khalili

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Carboxytherapy has been used in the treatment of autoimmune skin diseases such as psoriasis and morphea. Carboxytherapy has antioxidant effects, and leads to better tissue oxygenation, and release of growth factors. In this article, we decided to evaluate efficacy of combined carboxytherapy and narrowband‐ultraviolet B (NB‐UVB) compared to NB‐UVB alone in the treatment of vitiligo. This is a prospective, split‐body double‐blind comparative study performed in patients with generalized stable vitiligo in acral areas and extremities referred to dermatology clinic of Afzalipour hospital in Kerman University of Medical Sciences. NB‐UVB was performed three times a week in non‐consecutive days for 4 months. In each patient, one lesion was randomly treated with carboxytherapy (weekly sessions for total of 16 sessions). Efficacy of treatment was evaluated by percentage of repigmentation of the lesions. Chi‐square test and analysis of variance test (ANOVA) were used to compare efficacy of treatment based on demographic features of the patients and clinical features of the lesions, respectively. Twenty‐eight patients with mean age of 32.35 ± 7.37 years old completed the study. At the end of the treatment, 37% of the patients in combination therapy group demonstrated more than 75% improvement compared to 0% in the monotherapy group (p = 0.001). There was no significant difference between either demographic features of the patients (age, sex, and skin phototypes) or duration of disease with efficacy of the treatment in both groups. Combination of carboxytherapy with NB‐UVB leads to higher percentage of repigmentation and patients' satisfaction compared to monotherapy with NB‐UVB.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Combination of carboxytherapy with narrowband‐ultraviolet B in the treatment of recalcitrant areas of vitiligo: A randomized clinical trial

Farajzadeh

Yazdanpanah

Khalili

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“… Growth factors that stimulate keratinocyte and fibroblast proliferation and improve their interaction with melanocytes to make them stable 12 . These multiple factors lead to the migration of melanocytes from peri‐lesional skin, thus allowing repigmentation 13–16 . Basic fibroblast growth factor (b‐FGF) enhances melanocyte migration, keratinocyte, and fibroblast proliferation 8 .…”

Section: Discussionmentioning

confidence: 99%

Efficacy of autologous platelet‐rich plasma in the treatment of vitiligo: A 10‐patient prospective study

Rekik

Mseddi

Kammoun

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Introduction Vitiligo is an autoimmune disorder characterized by loss of epidermal melanocytes. It has cosmetic and psychosocial impact. The objective of this paper is to evaluate the interest of platelet‐rich‐plasma in the treatment of vitiligo. Material and methods We conducted a prospective study between January 2019 and September 2021. Results Our descriptive study included 10 patients followed‐up for vitiligo refractory to conventional therapies. The mean age was 36.2 years. Sex ratio was 0.25. Prior to platelet‐rich‐plasma treatment, vitiligo was stable in all cases. The mean number of platelet‐rich‐plasma sessions received by our patients was 2.6 (1–6). A visible improvement of lesions was obtained after a mean of 1.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. An improvement of more than 75% (grade 4) was noted in 2 cases after a mean duration of 5.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. A percentage of improvement between 50 and 74% (grade 3) was obtained for 2 patients. Four patients had an improvement of less than 25% (grade 1) after a mean of 1.75 sessions. There was no recurrence of depigmentation after a mean follow‐up of 6 months (1 to 24 months). Conclusion Our series proves the benefit of platelet‐rich‐plasma in the treatment of vitiligo. It is a safe and promising option for stable lesions in different body sites with few side effects.

show abstract

Efficacy and Safety of Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial

Tang

Chang

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction The purpose of this study was to assess the efficacy and safety of fractional CO 2 laser combined with halometasone cream in patients with moderate-to-severe chronic hand eczema (CHE). Methods A prospective, single-center, parallel-group, open-label randomized trial including 67 patients with moderate-to-severe CHE was carried out. Patients were randomly assigned to group A ( n = 33, fractional CO 2 laser once every 4 weeks 1–2 times and halometasone cream twice daily for 8 weeks) or group B ( n = 34, halometasone cream alone twice daily for 8 weeks). The primary endpoint was the proportion of patients achieving treatment success at week 12 in each group. Secondary endpoints included differences between groups in the change of hand eczema severity index (HECSI), patient global assessment (PaGA), dermatology life quality index (DLQI), and quality of life in hand eczema questionnaire (QOLHEQ) from baseline to week 12. Relapse rate and adverse effects were also recorded. Results A total of 29 patients in each group completed the trial. At week 12, the treatment success rate was 62.1% (18/29) in group A and 27.6% (8/29) in group B ( p = 0.009). At week 12, HECSI, PaGA, DLQI, and QOLHEQ all decreased compared with baseline in both groups ( p < 0.05). HECSI, DLQI, and QOLHEQ decreased more in group A than group B ( p = 0.014, 0.010, and 0.014, respectively), but there was no significant difference in change of PaGA between the two groups (1.0 versus 3.0, p = 0.419). Among patients achieving treatment success, 11.1% (2/18) patients in group A and 50.0% (4/8) patients in group B relapsed at week 24 ( p = 0.011). Skin pigmentation was the most common adverse effect. Conclusions For patients with moderate-to-severe CHE, fractional CO 2 laser combined with halometasone cream is more effective than halometasone cream alone, with few adverse effects. Trial Registration Number ChiCTR2100051948.

show abstract

Fractional CO2 laser, platelet rich plasma and narrow band ultraviolet B in the treatment of Vitiligo (A randomized clinical trial)

Cited by 19 publications

References 17 publications

Combination of carboxytherapy with narrowband‐ultraviolet B in the treatment of recalcitrant areas of vitiligo: A randomized clinical trial

Combination of carboxytherapy with narrowband‐ultraviolet B in the treatment of recalcitrant areas of vitiligo: A randomized clinical trial

Efficacy of autologous platelet‐rich plasma in the treatment of vitiligo: A 10‐patient prospective study

Efficacy and Safety of Fractional CO2 Laser Combined with Halometasone Cream for Treatment of Moderate-to-Severe Chronic Hand Eczema: A Prospective, Single-Center, Parallel-Group, Open-Label Randomized Trial

Contact Info

Product

Resources

About